Above portion: Turing Pharmaceuticals’ December 18, 2015 press release claiming that “Daraprim remains available and unaffected by [Martin Shkreli’s insane price hike],” and “No patient needing Daraprim will be denied access.” Below portion: A clip from the provider newsletter published in January 2016 from a major local non-profit health insurance company in Minnesota that administers a large amount of state Medicaid coverage, Medicare supplement plans, commercial employer plans, and individual state exchange plans (i.e. every part of the insurance market) stating that because of the massive cost increase, patients can no longer obtain this medication without prior authorization.
Will Turing Pharmaceuticals be filling out all the prior authorization forms for the 2,000 people affected, or...?